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Abstract
The ryanodine receptor antagonist dantrolene inhibits calcium release from the sarcoplas-
mic reticulum and reduces cardiac ischaemia-reperfusion injury (IRI) in global warm ischae-
mia models however the cardioprotective potential of dantrolene under hypothermic
conditions is unknown. This study addresses whether the addition of dantrolene during car-
dioplegia and hypothermic storage of the donor heart can improve functional recovery and
reduce IRI. Using an ex vivo isolated working heart model, Wistar rat (3 month and 12
month) hearts were perfused to acquire baseline haemodynamic measurements of aortic
flow, coronary flow, cardiac output, pulse pressure and heart rate. Hearts were arrested and
stored in Celsior preservation solution supplemented with 0.2–40 μM dantrolene for 6 hours
at 4˚C, then reperfused (15 min Langendorff, 30 min working mode). In 3-month hearts, sup-
plementation with 1 μM dantrolene significantly improved aortic flow and cardiac output
compared to unsupplemented controls however lactate dehydrogenase (LDH) release and
contraction bands were comparable. In contrast, 40 μM dantrolene-supplementation yielded
poor cardiac recovery, increased post-reperfusion LDH but reduced contraction bands. All
3-month hearts stored in dantrolene displayed significantly reduced cleaved-caspase 3
intensities compared to controls. Analysis of cardioprotective signalling pathways showed
no changes in AMPKα however dantrolene increased STAT3 and ERK1/2 signaling in a
manner unrelated to functional recovery and AKT activity was reduced in 1 μM dantrolene-
stored hearts. In contrast to 3-month hearts, no significant improvements were observed in
the functional recovery of 12-month hearts following prolonged storage in 1 μM dantrolene.
Conclusions: Dantrolene supplementation at 1 μM during hypothermic heart preservation
improved functional recovery of young, but not older (12 month) hearts. Although the molec-
ular mechanisms responsible for dantrolene-mediated cardioprotection are unclear, our
studies show no correlation between improved functional recovery and SAFE and RISK
pathway activation.
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Introduction
A major goal in heart transplantation is preventing and mitigating ischaemic injury during
organ procurement, and cold ischaemia during storage and transportation. The failure of
ATP-dependent ion pumps during hypoxia causes detrimental increases in cytosolic Na+ and
Ca2+ concentrations[1]. Warm blood reperfusion and reoxygenation of the donor heart causes
further injury due to rapid ATP flux and increased Ca2+ release from the sarcoplasmic reticu-
lum (SR) via ryanodine receptors (RyRs). High cytosolic Ca2+ concentrations promotes rapid
Ca2+ oscillations and calcium-induced calcium release contributing towards mitochondrial
Ca2+ uptake, mitochondrial permeability transition pore (mPTP) opening and subsequent
apoptosis and necrosis[2]. Pharmacological modulation of Ca2+ release from RyRs is one
approach that could reduce ischaemia-reperfusion injury (IRI) of the donor heart caused by
Ca2+ overload.
The ryanodine receptor antagonist dantrolene is clinically used to treat malignant hyper-
thermia in individuals with a mutation in the skeletal muscle RyR1 isoform[3, 4]. Dantrolene
also binds the cardiac RyR2 isoform[3, 5] and inhibits SR Ca2+ release by altering RyR confor-
mation from an ‘unzipped’ conformation under stress conditions (e.g., hypoxia) to a ‘zipped’
conformational state that retains calmodulin binding and prevents diastolic Ca2+ release[6–8].
Several studies have shown the anti-arrhythmogenic effects of dantrolene. Dantrolene inhib-
ited slow inward currents and prolonged the action potential duration in isolated sinoatrial
and atrioventricular nodes [9] and reduced arrhythmias in a murine model of exercise-
induced ventricular tachycardia that contain a RyR2 mutation analogous to the human cate-
cholaminergic polymorphic ventricular tachycardia (CPVT)[10]. Spontaneous Ca2+ release
events from SR RyRs were significantly reduced in dantrolene-treated CPVT myocytes and
heart failure-derived cardiomyocytes [11–13]. Also, dantrolene administration during cardio-
pulmonary resuscitation aided the return of spontaneous circulation after defibrillation in a
porcine VF model[14]. In the same study, dantrolene infusion of Langendorff-perfused rabbit
hearts increased resistance to isoproterenol-induced VF and reduced diastolic Ca2+ release
from RyR2[14]. These studies show that dantrolene treatment can correct abnormal cardiac
physiological events caused by altered Ca2+ release.
Previous studies have used various myocardial ischaemia models to test whether dantrolene
can reduce IRI [15–18]. Administration of dantrolene to Langendorff-perfused hearts prior to
global normothermic ischaemia significantly improved left ventricular developed pressure
compared to vehicle controls[16] and dantrolene administration at reperfusion elicited a dose-
dependent protective effect indicated by reduced LDH release and tissue necrosis[18]. Despite
biochemical indicators demonstrating reduced IRI, dantrolene doses exceeding 16 μM exerted
a negative inotropic effect[18]. In a similar study, dantrolene administration (25 μM or
100 μM) during the initial 15 minute reperfusion reduced creatine kinase release despite a lack
of functional recovery across all treatment groups[17]. In an isoproterenol-induced myocar-
dial ischemia model, dantrolene administration reduced cardiac troponin levels, an indicator
of myocardial cellular injury, and reduced the severity of histological cardiac damage indicated
by eosinophilia and interstitial oedema[15]. These studies provide evidence supporting a pro-
tective role for dantrolene in experimental warm ischaemia models. However, to our knowl-
edge, studies testing the cardioprotective efficacy of dantrolene during prolonged cold
ischaemia in the context of donor hearts have not been performed. The present study uses an
ex vivo rodent working heart reperfusion model to test whether dantrolene supplementation
of Celsior cardiac arresting and preservation solution during 6 hour hypothermic storage is
beneficial for: i) cardiac functional recovery; ii) necrosis and apoptotic indices; iii) pro-survival
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signalling kinases ERK, AKT, STAT3, and AMPKα. Identifying novel agents that further
reduce IRI and improve cardiac recovery of donor hearts after prolonged cold ischaemia has
the potential to increase donor heart availability and alleviate heart transplant wait lists.
Materials and methods
Animals
Male Wistar rats aged approximately three-months (325-440g) and twelve-months (650-940g)
were obtained from the Animal Resources Centre (Canning Vale, WA, Australia) and Charles
River Laboratories (Kingston, NY, USA) respectively. Animals received humane care in com-
pliance with the National Health and Medical Research Council (Australia) guidelines. All pro-
cedures were approved by the Animal Ethics Committee of the Garvan Institute of Medical
Research (Sydney, Australia). Animal Research Authority Ref #12/28, #15/28, and #15/05.
Ex vivo perfusion model
The isolated working rat heart model used has been previously described[19–22]. Rats were
anesthetized with an intraperitoneal injection of ketamine (80mg/kg; Cenvet Australia, Kings
Park, NSW, Australia) and xylazine (10mg/kg; Provet, Eastern Creek NSW, Australia). Prior
to heart excision, 150 IU heparin (Pfizer, West Ryde, NSW, Australia) was administered via
the renal vein. Once excised, the heart was cannulated and immediately perfused retrogradely
on a Langendorff perfusion apparatus with Krebs-Henseleit buffer (KHB) for 10 mins at 37˚C
(composition (mM): NaCl 118; KCl 4.7; MgSO4 1.2; KH2PO4 1.2; NaHCO3 25; CaCl2 1.4; glu-
cose 11; pH 7.3–7.4) at a hydrostatic pressure of 100 cm H2O. After stabilization, perfusion
was switched to working mode and perfused via a left atrial cannula at a hydrostatic pressure
of 15 cm H2O. The working heart ejected perfusate into the aortic cannula against a fixed pres-
sure (100 cm H20) for 15 min, and functional parameters of aortic pressure, aortic flow (AF),
coronary flow (CF), cardiac output (CO), heart rate (HR), and pulse pressure (PP) continu-
ously measured. Hearts with a baseline AF<35 ml/min, HR <200 bpm, or CF <10 ml/min
were excluded. Coronary effluent was collected at the end of baseline measurements.
Prolonged IRI protocol
Hearts were arrested by infusion of Celsior preservation solution (4˚C; Genzyme, Naarden,
Netherlands) alone (control) or with dantrolene sodium salt (0.2, 0.4, 1, 4, and 40 μM; Sigma-
Aldrich, St. Louis, MO, USA) into the coronary circulation for 3 min from a reservoir 60 cm
above the heart. Hearts were removed from the Langendorff apparatus with the cannulae kept
in situ and stored at 4˚C in 100 ml of the designated arresting solution for 6 hours. After stor-
age, hearts were placed on the perfusion apparatus and reperfused in Langendorff mode for 15
min before switching to working mode. Functional parameters were recorded for 30 min dur-
ing working mode. Cardiac functional recovery at the end of reperfusion was calculated as a
percentage of the pre-storage baseline value.
Assessment of lactate dehydrogenase release
Coronary effluent was collected at baseline, 15 min, 30 min, and 45 min reperfusion time
points. Myocardial injury based on lactate dehydrogenase levels was assessed using the In
Vitro Toxicology Assay Kit (TOX7; Sigma-Aldrich) according to manufacturer’s instructions.
Results are expressed as arbitrary units of colorimetric absorbance (490 nm) following normal-
isation with coronary flow values[23].
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Western blot analysis
Left ventricular tissue collected after reperfusion was snap frozen and stored at -80˚C. Tissue
homogenates were processed as previously described[21]. Protein (30 μg) was added to Laemlli
sample buffer (BioRad Laboratories, Gladesville, NSW, Australia) then heated at 95˚C for 10
min and run on a 4–20% Mini-PROTEAN TGX precast gel (BioRad Laboratories) at 80 V for
15 min then 120 V for 60 min. Proteins were transferred onto an Immobilon-P PVDF 0.45 μm
membrane (Merck Millipore, Bayswater, VIC, Australia) at 100 V for 80 min in transfer buffer
containing 20% methanol. Membranes were washed in TBS-0.1% Tween (TBS-T) for 5 min,
blocked for 1 h at room temperature in 5% (w/v) skim milk+TBS-T, then washed in TBS-0.1%
Tween (TBS-T) for 5 min. Membranes were incubated with primary antibody overnight at
4˚C in TBS-T. Primary antibodies (1:1000; Cell Signaling, Beverly, MA, USA): phospho-
AMPKα (Thr172, 40H9), AMPKα, phospho-p44/42 MAPK (ERK1/2; T202/Y204), p44/42
MAPK, phospho-AKT (S473), AKT, phospho-STAT3 (Tyr705), STAT3 (79D7), phospho-con-
nexin 43 (S368), calmodulin, α-tubulin (1:3000; Sigma-Aldrich). Membranes were incubated
with secondary anti-rabbit (1:2000 in 5% skim milk + TBS-T) or anti-mouse (1:5000 in 1%
BSA + TBS-T) IgG-horseradish peroxidase antibody (both GE healthcare, Rydalmere, NSW,
Australia) for 2 h at room temperature. Protein bands were visualized using SuperSignal West
Pico Chemiluminescent (Life Technologies, Scoresby, VIC, Australia), digitized, and quanti-
fied using ImageJ (Version 1.48v, National Institutes of Health, USA).
Histopathology
Myocardial samples were collected after reperfusion and stored in 4% paraformaldehyde
(Sigma-Aldrich). Formalin-fixed tissues were paraffin embedded and 5 μm sections were
stained with hematoxylin and eosin (H&E). Blinded analysis of contraction bands was per-
formed by an experienced anatomical pathologist (MRQ) and quantified as the average num-
ber of contraction bands in four high-powered (40X) fields. Cleaved-caspase 3 (1:300,
ab13847, Abcam, Cambridge, MA, USA) staining was quantified using ImageJ (National Insti-
tutes of Health, Bethesda, MD, USA) and expressed as the average percentage of cleaved-cas-
pase 3 positive stained tissue calculated from six high-powered (40X) fields for each heart
section.
Statistical analysis
Statistical analysis was performed using GraphPad Prism (Version 7.03; GraphPad Software
Inc., La Jolla, CA, USA). For comparison of baseline cardiac haemodynamics before and after
dantrolene addition, data was analysed using a Wilcoxon matched-pairs sign rank test. Recov-
ery from baseline data was analysed using Mann-Whitney unpaired t test versus control
group. Functional post-reperfusion data and LDH results were analysed using a two-way
ANOVA with Dunnett’s multiple comparisons test. Histopathology and densitometry results
were analysed using a one-way ANOVA with Holm-Sidak’s multiple comparisons test. A p
value <0.05 was considered statistically significant.
Results
Effects of dantrolene on baseline cardiac haemodynamics
To test whether dantrolene would affect baseline cardiac function, hearts were perfused with
KHB for 10 min in Langendorff mode to stabilise the heart and then perfused with KHB for 15
min in working mode. Compared to KHB alone, the addition of 4 μM dantrolene to the per-
fusate during working mode did not alter baseline AF, CF, CO and PP (Table 1). A small
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increase in HR was observed following the addition of 4 μM dantrolene however this was not
statistically significant. Overall 4 μM dantrolene administered during pre-storage perfusion
does not alter baseline cardiac haemodynamics.
Effects of dantrolene-supplementation during cold storage on donor heart
functional recovery
To test whether dantrolene-supplementation would affect the cardiac recovery after prolonged
cold storage of the donor heart, Celsior preservation solution was supplemented with either
0.2 μM, 0.4 μM, 1 μM, 4 μM, or 40 μM dantrolene. Of the concentrations tested, supplementa-
tion with 1 μM dantrolene significantly increased CO during the 30 minute working heart
reperfusion compared to unsupplemented control (Fig 1A). This observation was primarily
due to a significant increase in AF as CF was only slightly improved with 1 μM dantrolene sup-
plementation (Fig 1B and 1C). In contrast, hearts supplemented with 40 μM dantrolene
showed significantly worse AF, CF and CO recovery throughout the 30 minute reperfusion
period (Fig 1A–1C). A significant impairment in PP was evident when hearts were stored at
the lower dose of 0.2 μM or the higher dose of 40 μM dantrolene compared to unsupplemented
controls (Fig 1D). Similar effects of dantrolene-supplementation on cardiac recovery were also
observed when functional recovery was analysed as a percentage of its corresponding baseline
haemodynamic value, with 1μM dantrolene-supplemented hearts showing significantly
improved AF and CO whereas hearts supplemented with 40 μM dantrolene showed the poor-
est AF and CO recovery (Fig 2A and 2B). There were no differences in HR recovery between
unsupplemented controls and dantrolene-supplemented groups (Fig 2C). These data indicate
that of the concentrations tested in the current study, supplementation of hearts with 1 μM
dantrolene yielded the greatest improvement in cardiac functional recovery after prolonged
cold storage.
Effects of dantrolene-supplementation during cold storage on donor heart
cellular injury
To assess cellular injury of the donor hearts following cold storage, LDH levels were measured
in the coronary effluent collected during reperfusion. Compared to unsupplemented controls,
LDH release from hearts supplemented with 0.2–4 μM dantrolene were comparable, however,
supplementation with 40 μM dantrolene caused a significant increase in LDH release by 45
min reperfusion (Fig 3A). To assess apoptosis at the end of the reperfusion, tissue sections
were stained for cleaved-caspase 3 (Fig 3B). Compared to unsupplemented controls, all dan-
trolene-stored hearts showed a significant reduction in cleaved-caspase 3 positive stained tis-
sue (Fig 3C). To further assess cellular injury in dantrolene-supplemented hearts, tissue
Table 1. Effect of dantrolene on baseline cardiac haemodynamics (mean ± SD).
Functional parameter KHB only (n = 4) KHB + 4μM dantrolene (n = 4) P value�
Aortic flow (ml/min) 42.73 ± 6.41 45.36 ± 3.55 0.625
Coronary flow (ml/min) 20.75 ± 4.03 23.25 ± 4.65 0.125
Cardiac Output (ml/min) 63.48 ± 8.22 68.61 ± 7.01 0.250
Heart rate (bpm) 244.26 ± 41.33 274.43 ± 15.78 0.375
Pulse Pressure (mmHg) 50.06 ± 17.04 43.12 ± 16.92 0.875
KHB, Krebs-Henseleit Buffer.
� p values were calculated using the Wilcoxon matched-pairs signed rank test.
https://doi.org/10.1371/journal.pone.0205850.t001
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Fig 1. Cardiac functional recovery during 30 minutes working mode reperfusion after dantrolene-supplementation during prolonged cold storage. (A) Cardiac
output, ml/min; (B) aortic flow, ml/min; (C) coronary flow, ml/min; (D) pulse pressure, mmHg. Data shown as mean ± SEM. � p<0.05 versus control, two-way
ANOVA with Dunnett’s multiple comparisons test, n = 4–8 per group.
https://doi.org/10.1371/journal.pone.0205850.g001
Fig 2. Cardiac functional recovery at the end of 30 minutes working mode reperfusion as a percentage of baseline
value. (A) aortic flow; (B) cardiac output, (C) heart rate. Bars represent mean ± SEM; � p< 0.05 versus control, Mann-
Whitney unpaired t test; n = 4–8 per group.
https://doi.org/10.1371/journal.pone.0205850.g002
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sections were H&E stained and examined for the presence of contraction bands as a marker of
necrosis. Histological analysis showed that dantrolene did not alter the number of contraction
bands evident after reperfusion of cold-stored hearts except when stored in 40 μM dantrolene
which caused a 30% reduction in contraction bands (Fig 3D and 3E) but this did not reach sta-
tistical significance (ANOVA, p = 0.089). Despite improved recovery of 1 μM dantrolene-sup-
plemented hearts, this was not due to reduced contraction band necrosis or reduced apoptosis
since no distinction in LDH release, contraction bands, or cleaved-caspase 3 expression was
evident between the different dantrolene concentration groups.
Cardioprotective-signaling in dantrolene-supplemented hearts
To elucidate the mechanism by which dantrolene was improving cardiac recovery, four signal-
ling pathways implicated in mediating cardioprotection were examined: i) the survivor activat-
ing factor enhancement (SAFE) pathway indicated by STAT3; ii)the reperfusion injury
survival kinase (RISK) pathway indicated by ERK1/2 and AKT; iii) AMPKα activation; and iv)
connexin 43 phosphorylation. Compared to control hearts, a significant increase in STAT3
phosphorylation was observed only in hearts supplemented with 0.2 μM dantrolene (Fig 4A).
An increase in ERK1/2 phosphorylation was observed in hearts supplemented with 4 μM dan-
trolene but not at lower dantrolene concentrations tested (Fig 4B). Contrary to increased RISK
signalling with respect to ERK1/2 phosphorylation, AKT phosphorylation was reduced in
hearts stored with 1 μM dantrolene (Fig 4C). No significant changes were observed in AMPKα
phosphorylation (Fig 4D). In contrast, hearts stored in 1 μM dantrolene trended towards
increased connexin 43 phosphorylation at S368 compared to control hearts, correlating with
improved functional recovery in these hearts.
Effects of dantrolene-supplementation during cold storage on functional
recovery in older hearts
Previous studies have shown that spontaneous Ca2+ release events of aged cardiomyocytes are
delayed in response to dantrolene treatment however this effect is not observed in cardiomyo-
cytes derived from young mice [24]. Since 1 μM dantrolene supplementation improved func-
tional recovery in young hearts, we tested whether dantrolene-mediated cardiac functional
recovery could be further improved after prolonged cold storage of older hearts. Despite a
slight trend towards increased CO after 30 minute reperfusion, the observed recovery in 3
month old hearts was not observed in 12 month old hearts (Fig 5).
Discussion
Previous studies have shown that dantrolene can minimise IRI in global warm ischaemia mod-
els however whether dantrolene can protect the heart after prolonged periods of cold ischae-
mia has not been demonstrated. The present study reports for the first time the effects of
dantrolene on cardiac functional recovery in the context of prolonged donor heart cold stor-
age. We show that supplementation of hearts with 1 μM dantrolene during hypothermic
Fig 3. Analysis of cardiac cellular injury post-reperfusion after 6h storage in Celsior alone (control) or dantrolene-supplemented. (A) Lactate dehydrogenase
release in coronary effluent collected at baseline and during reperfusion. Bars represent mean ± SEM; n = 4–7 per group; � p<0.05 compared to control at 45 min
reperfusion, Dunnett’s multiple comparisons test. (B) Cumulative cleaved-caspase 3 analysis presented as the percentage of cleaved-caspase 3 positive tissue per six
high-powered (40X fields). Bars represent mean ± SEM; n = 4 per group �p< 0.05 versus control, Mann-Whitney unpaired t test. (C) Representative cleaved-caspase
3 staining of hearts stored in Celsior alone (control) or supplemented with 0.4–40 μM dantrolene. (D) Contraction band quantification in H&E sections as the
average count per four high powered (40X) fields. Bars represent mean ± SEM; n = 4–7 per group; (E) Representative H&E staining depicting contraction bands
(black arrows) of hearts stored in Celsior alone (control) or supplemented with 0.2–40 μM dantrolene.
https://doi.org/10.1371/journal.pone.0205850.g003
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storage significantly improves aortic flow and cardiac output. In contrast, higher doses at
40 μM dantrolene were toxic and abolished cardiac recovery. The poor functional recovery
observed at 40 μM dantrolene can be explained in part by myocardial necrosis and by the
direct negative effect on myocardial contraction, as indicated by increased LDH release and
reduced contraction bands respectively. Further, the inhibitory effect of dantrolene on Ca2+
release from the SR is likely to prevent reperfusion-induced hypercontracture caused by rapid
SR Ca2+ cycling[1, 25]. Contrary to our current observations, previous reports show a dose-
dependent reduction in LDH release [18]. However, a decrease in cardiac contractility has also
been shown due to the muscle relaxant properties of dantrolene at comparable doses[26].
The cardioprotective signalling responsible for the functional benefits of dantrolene during
ischaemia-reperfusion have not been reported. In our study, no changes were observed in
AMPKα activation in dantrolene-stored hearts. Contrasting results with respect to the RISK
signalling pathways were observed. Firstly, the increased ERK1/2 signalling is unlikely to
Fig 4. Cardioprotective signalling pathways in dantrolene-stored hearts. Representative western blots and cumulative densitometry analysis of (A) STAT3, (B) ERK1/
2, (C) AKT, (D) AMPKα, and (E) connexin 43 (S368). Representative blots of 3–4 biological replicates are shown. Densitometry was calculated from n = 7 biological
replicates for each group.
https://doi.org/10.1371/journal.pone.0205850.g004
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explain the observed functional benefit as there was no correlation with functional recovery.
Secondly, we observed a decrease in AKT phosphorylation in 1 μM dantrolene-stored hearts
which contradicts with the increased AKT phosphorylation typically observed in relation to
cardioprotection [27, 28]. The effect that dantrolene has on the aforementioned signalling
pathways has previously not been extensively reported. However, in skeletal muscle models of
caffeine-induced signalling, dantrolene does not alter AKT phosphorylation [29] but inhibits
AMPKα activation [30]. Also, dantrolene inhibits ERK1/2 phosphorylation in gonadotropin-
treated epithelial ovarian cancer cell lines [31]. To our knowledge, there are no reports on the
effects of dantrolene on STAT3 signalling however we observed significantly increased STAT3
phosphorylation at lower concentrations of dantrolene supplementation unrelated to func-
tional recovery. Of interest, the trend towards increased connexin 43 phosphorylation corre-
lating with improved cardiac recovery supports the notion of a cardioprotective role for
connexin 43. Despite the involvement of connexin 43 in gap junction formation and intercel-
lular communication [32], connexin 43 has also been implicated as a mediator of cardioprotec-
tion as heterozygous connexin 43 knockout mice show loss of cardioprotection in response to
ischaemic-preconditioning [33]. If connexin 43 is associated dantrolene-mediated cardiopro-
tection, it is likely related to the ability of dantrolene to reduce intracellular calcium flux as
dantrolene does not alter gap junction formation [34].
It is important to highlight that the narrow therapeutic dose range of dantrolene supple-
mentation that corresponded to a functional benefit presents a potential limitation for clinical
translation. Since dantrolene modulates calcium release from the SR, it is possible that the
functional and signalling effects are calcium-dependent and can be influenced by Ca2+ concen-
trations in the perfusion system. This held true in studies where variations in the Ca2+ concen-
tration of KHB buffer altered cardiac isometric force in the presence of dantrolene[35].
Another possibility is that at lower temperatures, dantrolene-mediated inhibition of calcium
release is reduced as observed in studies of the RyR1 channel [8]. Further, the structural con-
formation of RyR2 may restrict the binding of dantrolene under normal physiological condi-
tions [3]. However, ischaemia/reperfusion in itself significantly increases intracellular calcium
stores and may provide the required modification of the RyR2 dantrolene binding site [36, 37].
It has been proposed that dantrolene can preferentially access the RyR2 binding site when
the interdomain interactions are disrupted under conditions of cellular stress [6] such as with
Fig 5. Cardiac output during 30 minutes of working heart reperfusion of 12 month old hearts after 6h cold
storage in Celsior alone or supplemented with 1 μM dantrolene. Bars represent mean ± SEM; n = 7 per group.
https://doi.org/10.1371/journal.pone.0205850.g005
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ageing. Indeed, dantrolene corrected for calcium-induced dysfunction in aged cardiomyocytes
more so than in young cardiomyocytes [24] suggesting that dantrolene-mediated cardiopro-
tection may be more prominent in hearts from older donors. In our study the cardioprotective
benefit of 1 μM dantrolene-supplementation in 3-month hearts was not statistically significant
for 12-month hearts. It is possible that functional recovery of older hearts (i.e., 18-month) after
dantrolene-supplementation may show a larger difference compared to controls since previous
work from our laboratory using older hearts showed greater cardiac recovery in 18-month ver-
sus 12-month hearts [27]. However, in our experience, functional studies utilising donor
hearts 12 months and older present logistical challenges due to increased attrition and costs
associated with maintaining sufficient animals to guarantee enough numbers for experimental
groups. Due to the limited number of 12 month old animals available during our study, only
the optimal dantrolene concentration observed from our 3 month studies was tested, however,
significant changes in cardiac recovery may have been observed at different dantrolene doses.
In the current study, there are certain aspects of the experimental protocol that vary from a
clinical setting. Firstly, brain death or circulatory death have not been incorporated in our
model before harvesting the donor heart, which in itself can influence the extent of donor
heart recovery and would represent a clinical equivalent of our experimental model. Secondly,
the use of KHB (an oxygenated crystalloid buffer) for reperfusion is different from blood-
based reperfusion in a transplant setting. Experimentally, this can be tested using the techni-
cally challenging heterotopic rodent heart transplant model. However, the benefit of using
KHB perfusion is the absence of potentially detrimental white cells and other blood-borne
products that can confound the cardiac functional effects of potential cardioprotective agents
in our ex vivo model. Although it is possible that changing from KHB perfusion to blood-
based perfusion will negate any cardioprotective benefit for dantrolene, as was observed by
Preckel et. al.[17] where dantrolene showed creatine kinase reductions in a Langendorff perfu-
sion model of IRI but no improvement in myocardial infarct size in vivo. Thirdly, our protocol
contains heparin administration prior to harvesting the donor heart to minimise clot forma-
tion in the cardiac microvasculature that can contribute towards poor perfusion, however the
legislation on clinical antemortem heparin use varies between different transplant centres.
In conclusion, we have shown that dantrolene-supplementation improves functional recov-
ery after prolonged hypothermic storage of donor hearts from young but not older hearts. Our
study demonstrates a narrow therapeutic window for dantrolene suggesting that testing in a
clinically relevant model incorporating brain death may require further dose optimisation.
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